ActivePassive國際股票主動型ETF APIE 深 滬
等待開盤 06-26 09:30:00 美东时间
38.1979
+0.318
+0.84%
華盛通- 最 高38.2599
- 今 開38.15
- 成交量 1.03万股
- 最 低 37.91
- 昨 收 37.88
- 總市值 10.49亿
- 52周最高 39.19
- 市盈率 靜 --
- 換手率 0.04%
- 52周最低 30.7815
- 委 比 -11.11%
- 總股本 2745.00万
- 歷史最高 39.19
- 量 比 0.71
- 振 幅 0.92%
- 歷史最低 21.1363
- 每 手 1
- 風險率 2.22%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多BRIEF-Tensordyne Announces Tensordyne Napier
BRIEF-Tensordyne Announces Tensordyne Napier June 15 (Reuters) - Tensordyne: TENSORDYNE: ANNOUNCES TENSORDYNE NAPIER, WHICH CAN GENERATE UPTO $33 MILLION MORE REVENUE PER RACK PER YEAR THAN NVIDIA BLACKWELL TENSORDYNE: SECURED OVER DOZEN LOI FROM HYPERSCALER, NEOCLOUD, SOVEREIGN AI INFRASTRUCTURE OP
06-15 22:00
FACTBOX-What Bundibugyo Ebola vaccines and treatments are under development
FACTBOX-What Bundibugyo Ebola vaccines and treatments are under development Adds details on PHV vaccine candidate and funding in paragraphs 22 and 23 By Mariam Sunny and Jennifer Rigby June 9 (Reuters) - Global health authorities are racing to identify medical options to help contain an Ebola outbre
06-09 22:29
FACTBOX-What Bundibugyo Ebola vaccines and treatments are under development
FACTBOX-What Bundibugyo Ebola vaccines and treatments are under development Adds details on WHO recommendation throughout By Mariam Sunny and Jennifer Rigby May 29 (Reuters) - Global health authorities are racing to identify medical options to help contain an Ebola outbreak in eastern Democratic Rep
05-29 19:00
BRIEF-Nanobiotix Announces Preclinical Data On Improved Delivery, Safety Of LNP-DNA Immunotherapy
BRIEF-Nanobiotix Announces Preclinical Data On Improved Delivery, Safety Of LNP-DNA Immunotherapy April 20 (Reuters) - Nanobiotix SA NANOB.PA : ANNOUNCES PRECLINICAL DATA SUPPORTING IMPROVED BIOAVAILABILITY AND REDUCED TOXICITY FOR LNP-DNA IMMUNOTHERAPY PRECLINICAL EVALUATION ASSESSES NANOPRIMER'S P
04-20 14:39
BRIEF-Uber Expands Its Stake In Delivery Hero In 270 Million Euro Deal - FT
BRIEF-Uber Expands Its Stake In Delivery Hero In 270 Million Euro Deal - FT April 17 (Reuters) - UBER EXPANDS ITS STAKE IN DELIVERY HERO IN €270MN DEAL- FT UBER HAS REACHED AN AGREEMENT TO ACQUIRE AN ADDITIONAL 4.5% STAKE IN DELIVERY HERO, TO ACQUIRE DELIVERY HERO SHARES AT €20 APIECE - FT Source t
04-17 13:33
BRIEF-Lunai Bioworks Executes $20M Strategic Transaction At Fixed $1.50 Conversion, Acquiring Bbb Delivery Platform For Cns Alzheimer's Therapies With Broad Cns Delivery Applications
BRIEF-Lunai Bioworks Executes $20M Strategic Transaction At Fixed $1.50 Conversion, Acquiring Bbb Delivery Platform For Cns Alzheimer's Therapies With Broad Cns Delivery Applications Lunai Bioworks Inc LNAI.O : LUNAI BIOWORKS EXECUTES $20M STRATEGIC TRANSACTION AT FIXED $1.50 CONVERSION, ACQUIRING B
03-26 20:52
BRIEF-Crossbow Therapeutics Raises $77 Million In Series B Financing To Advance Development Of Tcr-Mimetic Antibody Therapies To Treat Cancer
BRIEF-Crossbow Therapeutics Raises $77 Million In Series B Financing To Advance Development Of Tcr-Mimetic Antibody Therapies To Treat Cancer March 18 (Reuters) - CROSSBOW THERAPEUTICS RAISES $77 MILLION IN SERIES B FINANCING TO ADVANCE DEVELOPMENT OF TCR-MIMETIC ANTIBODY THERAPIES TO TREAT CANCER S
03-18 20:32
BRIEF-Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(C)(4)
BRIEF-Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(C)(4) March 6 (Reuters) - Taysha Gene Therapies Inc TSHA.O : TAYSHA GENE THERAPIES ANNOUNCES INDUCEMENT GRANT UNDER NASDAQ LISTING RULE 5635(C)(4) Source text: ID:nGNX7nQfB2 Further company coverage: TSHA.O (( Reut
03-06 21:03
Orthofix Q4 sales slightly beat expectations, EBITDA beats
Orthofix Q4 sales slightly beat expectations, EBITDA beats Overview Medical technology firm's Q4 net sales slightly beat analyst expectations Adjusted EBITDA for Q4 beat analyst estimates Company reported strong free cash flow generation in Q4 Outlook Orthofix expects 2026 net sales between $850 mln
02-24 20:12
BioMarin Pharmaceutical's Q4 revenue up 17%, beats expectations
BioMarin Pharmaceutical's Q4 revenue up 17%, beats expectations Overview Biotechnology firm's Q4 revenue rose 17% yr/yr, beating analyst expectations Adjusted EPS for Q4 missed analyst expectations Outlook BioMarin expects 2026 total revenues between $3.325 bln and $3.425 bln Company anticipates 202
02-24 05:14
